ArticleeNeuro2025
The Beta Amyloid Core Hexapeptide Protects against Full-Length Beta Amyloid-Induced Alteration of Dendritic Spine Morphology and Density.
Article in eNeuro, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pathological levels of beta amyloid (Aβ) lead to disruption and elimination of synapses in brain as the result of direct neurotoxicity as well as neuroinflammation. The synaptic impact of beta amyloid includes altered morphology and reduced number of dendritic spines at excitatory synapses, evident in the brains of individuals with Alzheimer's disease. Here, we assessed the ability of an identified neuroprotective peptide, YEVHHQ, derived from the N-terminal domain of Aβ, known as the AβCore, to protect against Aβ-induced alterations in dendritic spines. Our approach involved both 2D and 3D imaging of spine morphology in hippocampal neuron cultures from mice of either sex, with the 3D imaging focusing on the postsynaptic density (PSD), as its morphology is tightly correlated with synaptic strength, and presynaptic terminal morphology and density to assess the impact on both sides of the synapse. We present evidence for uniform prevention by the AβCore of Aβ-induced reductions in spine cross-sectional size and density as well as PSD surface area and volume. In addition, the AβCore alone increased the presynaptic terminal volume in parallel to the reversal of Aβ-induced changes in spine and PSD size. Together, these results provide support for reversal of structural changes underlying the functional reversal by the AβCore of Aβ-induced impairment of synaptic dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.